Blog

GEn1E Lifesciences Granted Exclusive License for UMB Drug Portfolio Compound

PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and all-fields license to the University of Maryland, Baltimore’s (UMB) specific and function selective p38a kinase inhibitor program.

GEn1E is developing cures for inflammatory diseases based on a next-generation p38a kinase inhibitor program. The first indication is acute respiratory distress syndrome (ARDS) followed by other disease areas. ARDS is a life-threatening inflammatory condition with no FDA-approved treatment and a 40% mortality rate. ARDS will be followed by development of programs for other inflammatory and age-related diseases.

“UM Ventures originally invested in the specific p38a kinase inhibitor program to help advance it to a licensable stage,” said Phil Robilotto, Associate Vice President, Office of Technology Transfer at UMB and Director of UM Ventures. “To have GEn1E, a Y Combinator-backed company, see the potential in this therapeutic program and develop it is very exciting for the UMB team.”

Click here to read the entire press release.